• TRADE NAME: Recarbrio (MSD)
• INDICATIONS: Patients 18 years of age and older who have limited, or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections
  
• CLASS: Antibiotic, Antibiotic; carbapenem (imipenem), Antimicrobial, Beta-lactamase inhibitor (relebactam), Renal dehydropeptidase inhibitor (cilastatin)
• HALF-LIFE: 1 hour (imipenem); 1.2 hours (relebactam); 1 hour (cilastatin)

FDA APPROVAL DATE: 07/16/2019

Ganciclovir, Valproic Acid

PREGNANCY CATEGORY: N/A
Insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with imipenem, cilastatin, or relebactam in pregnant women.